Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525372 | 0.91 | BTK (0.44) | BTKGAAEPHX1CA1CA2 | |
| SCHEMBL11947774 | 0.91 | BTK (0.44) | BTKGAAEPHX1CA1CA2 | |
| SCHEMBL14853197 | 0.88 | GAA (0.48) | BTKGAAEPHX1CA1CA2 | |
| SCHEMBL2226229 | 0.86 | BTK (0.56) | BTKGAAEPHX1CA1CA2 | |
| SCHEMBL2226232 | 0.86 | BTK (0.56) | BTKGAAEPHX1CA1CA2 | |
| SCHEMBL12439636 | 0.86 | BTK (0.56) | BTKGAAEPHX1CA1CA2 | |
| SCHEMBL20583619 | 0.84 | BTK (0.45) | BTKGAAEPHX1CTSKKMT2A | |
| SCHEMBL573789 | 0.82 | GAA (0.61) | BTKGAAEPHX1CA1CA2 | |
| SCHEMBL4492849 | 0.82 | BTK (0.58) | BTKGAAEPHX1CA1CA2 | |
| SCHEMBL21553267 | 0.81 | BTK (0.55) | BTKGAAEPHX1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071549-B | PDE1 inhibitors | H.隆德贝克有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-108513574-B | N-sulfonylated pyrazolo [3, 4-b ] pyridine-6-carboxamides and methods of use | 艾伯维公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| EP-3442975-B1 | 1,5-DIHYDRO-4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDIN-4-ONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2020-07-29 | — | — | EP | disclosed |
| EP-3442975-B1 | 1,5-DIHYDRO-4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDIN-4-ONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2020-07-29 | — | — | EP | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-20200102316-A1 | 1,5-DIHYDRO-4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDIN-4-ONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2020-04-02 | — | — | US | disclosed |
| US-10538525-B2 | 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-01-21 | — | — | US | disclosed |
| EP-2421366-B1 | HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8486946-B2 | Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130102599-A1 | PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
| WO-2013051639-A1 | PYRAZOLOQUINOLINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2013-04-11 | — | — | WO | disclosed |
| US-8293744-B2 | Heterocyclic fused cinnoline M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2398324-A1 | PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110301167-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-08 | — | — | US | disclosed |
| WO-2010096338-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102316-A1 | 1,5-DIHYDRO-4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDIN-4-ONES AS PDE1 INHIBITORS | PDE4A, PDE4B, PDE12 | BTK 3918/4885GAA 220/4885EPHX1 287/4885 |
| US-20110301167-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, MTNR1A | BTK 3993/4885GAA 3258/4885EPHX1 2993/4885 |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | PDE2A, PDE3A, PDE3B | BTK 1629/4885GAA 2015/4885EPHX1 991/4885 |
| US-10538525-B2 | 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors | PDE4A, PDE4B, PDE12 | BTK 3918/4885GAA 220/4885EPHX1 287/4885 |
| US-20130102599-A1 | PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, MTNR1A | BTK 3993/4885GAA 3258/4885EPHX1 2993/4885 |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, CHRM3, P2RY1 | BTK 788/4885GAA 3267/4885EPHX1 3223/4885 |
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | CHRM1, CNR1, CHRNA7 | BTK 2756/4885GAA 2766/4885EPHX1 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.